Genitourinary Cancers

Brian Rini, MD, details recent data in renal cell carcinoma surrounding the utility of KIM-1 as a potential biomarker and next steps for KIM-1 research.

Marc Machaalani, MD, discusses how inhibition of AXL and c-Met may prevent acquired resistance to c-Met inhibitors in renal cell carcinoma.

Razane El Hajj Chehade, MD, discusses a retrospective study of risk factors for irAEs in patients with metastatic renal cell carcinoma.

The addition of nivolumab to tivozanib did not improve PFS in advanced metastatic renal cell carcinoma following prior immune checkpoint inhibition

Razane El Hajj Chehade, MD, discusses the association between different histologic subtypes in renal cell carcinoma and the risk of developing immune-related adverse effects.

Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.

Brian I. Rini, MD, FASCO discusses findings from an exploratory analysis of the phase 3 KEYNOTE-426 study.

The National Comprehensive Cancer Network has published their updated Clinical Practice Guidelines in Oncology for kidney cancer.

The addition of ipilimumab to cabozantinib plus nivolumab was safe and showed notable efficacy in patients with rare genitourinary cancers.

Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.

Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.

Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.

Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.

Sumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

The FDA has granted fast track designation to ADI-270 for advanced clear cell renal cell carcinoma after an immune checkpoint inhibitor and VEGF inhibitor.

Vivek Subbiah, MD, discusses the rationale for combining sapanisertib with ziv-aflibercept in recurrent metastatic solid tumors, including kidney cancer.

Sumanta Kumar Pal, MD, FASCO, highlights key renal cell carcinoma research presented at the 2024 ASCO Annual Meeting, including early data with DFF332.